GlassScriptPhysician profile
Kara L Brantley
NPI 1720181530
$3,946.83
in general payments reported to CMS, 2019-2025
29 companies · $472 in 2025
The $472 reported for 2025 was more than what 79% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $504 · 2020: $364 · 2021: $829 · 2022: $661 · 2023: $738 · 2024: $378 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,588.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,366.98 | 2019-2025 | Lo Loestrin Fe, Ubrelvy, Qulipta |
| Astellas Pharma US INC | $782.10 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $250.75 | 2019-2025 | |
| Organon LLC | $232.20 | 2022-2025 | Nexplanon, Jada System |
| Hologic Sales and Service, LLC | $175.00 | 2019-2025 | Novasure, Myosure Tissue Removal Device |
| Novo Nordisk INC | $154.50 | 2019-2023 | Wegovy, Saxenda |
| Exeltis, USA INC. | $136.14 | 2020-2025 | Slynd |
| Myriad Women'S Health, INC. | $132.07 | 2023 | Myrisk |
| Medtronic, INC. | $91.66 | 2023 | Sonicision |
| Allergan, INC. | $78.92 | 2019-2020 | |
| Davol INC. | $68.44 | 2022-2024 | Arista Ah Flexitip |
| Biohaven Pharmaceuticals, INC. | $54.10 | 2021 | |
| Becton, Dickinson and Company | $52.01 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.09 | 2020-2022 | |
| Mayne Pharma Commercial LLC | $37.65 | 2023-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $34.18 | 2020-2021 | |
| Coopersurgical, INC. | $29.59 | 2019 | |
| Therapeuticsmd, INC. | $29.38 | 2020-2022 | |
| Evofem Biosciences, INC. | $26.02 | 2021 | |
| Merck Sharp & Dohme LLC | $23.42 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.03 | 2025 | |
| Currax Pharmaceuticals LLC | $17.86 | 2024 | Onzetra Xsail, Contrave |
| Dexcom, INC. | $17.63 | 2025 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $17.25 | 2020 | |
| Amgen INC. | $16.46 | 2023 | Evenity, Prolia |
| Sumitomo Pharma America, INC. | $15.99 | 2025 | Gemtesa |
| Minerva Surgical, INC | $15.17 | 2023 | |
| Boston Scientific Corporation | $13.61 | 2019 | |
| Lupin INC. | $12.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Brantley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.